138 related articles for article (PubMed ID: 35710258)
1. cfDNA as a surrogate marker for COVID-19 severity in patients with influenza-like symptoms with and without SARS-CoV-2 infections in general practice: a study protocol for a prospective cohort study.
Dehnen D; Neuberger E; In der Schmitten J; Giagkou E; Simon P; Botzenhardt S
BMJ Open; 2022 Jun; 12(6):e058647. PubMed ID: 35710258
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
[TBL] [Abstract][Full Text] [Related]
4. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
5. Serial measurements in COVID-19-induced acute respiratory disease to unravel heterogeneity of the disease course: design of the Maastricht Intensive Care COVID cohort (MaastrICCht).
Tas J; van Gassel RJJ; Heines SJH; Mulder MMG; Heijnen NFL; Acampo-de Jong MJ; Bels JLM; Bennis FC; Koelmann M; Groven RVM; Donkers MA; van Rosmalen F; Hermans BJM; Meex SJ; Mingels A; Bekers O; Savelkoul P; Oude Lashof AML; Wildberger J; Tijssen FH; Buhre W; Sels JEM; Ghossein-Doha C; Driessen RGH; Kubben PL; Janssen MLF; Nicolaes GAF; Strauch U; Geyik Z; Delnoij TSR; Walraven KHM; Stehouwer CD; Verbunt JAMCF; Van Mook WNKA; van Santen S; Schnabel RM; Aries MJH; van de Poll MCG; Bergmans D; van der Horst ICC; van Kuijk S; van Bussel BCT
BMJ Open; 2020 Sep; 10(9):e040175. PubMed ID: 32994259
[TBL] [Abstract][Full Text] [Related]
6. Evidence for the utility of cfDNA plasma concentrations to predict disease severity in COVID-19: a retrospective pilot study.
Hoeter K; Neuberger E; Fischer S; Herbst M; Juškevičiūtė E; Enders K; Rossmann H; Sprinzl MF; Simon P; Bodenstein M; Schaefer M
PeerJ; 2023; 11():e16072. PubMed ID: 37744227
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium during 1 year of the COVID-19 epidemic: prospective cohort study protocol.
Adriaenssens N; Scholtes B; Bruyndonckx R; Verbakel JY; De Sutter A; Heytens S; Van den Bruel A; Desombere I; Van Damme P; Goossens H; Buret L; Duysburgh E; Coenen S
BMJ Open; 2022 Jan; 12(1):e054688. PubMed ID: 35105642
[TBL] [Abstract][Full Text] [Related]
8. A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: A structured summary of a study protocol for a randomized controlled trial.
Sharma A; Sharma C; Raina S; Singh B; Dadhwal DS; Dogra V; Gupta S; Bhandari S; Sood V
Trials; 2021 Jul; 22(1):451. PubMed ID: 34266452
[TBL] [Abstract][Full Text] [Related]
9. Cell-free DNA maps COVID-19 tissue injury and risk of death and can cause tissue injury.
Andargie TE; Tsuji N; Seifuddin F; Jang MK; Yuen PS; Kong H; Tunc I; Singh K; Charya A; Wilkins K; Nathan S; Cox A; Pirooznia M; Star RA; Agbor-Enoh S
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33651717
[TBL] [Abstract][Full Text] [Related]
10. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
11. Clinical Evaluation of BD Veritor SARS-CoV-2 and Flu A+B Assay for Point-Of-Care System.
Christensen K; Ren H; Chen S; Cooper CK; Young S
Microbiol Spectr; 2022 Apr; 10(2):e0180721. PubMed ID: 35412847
[TBL] [Abstract][Full Text] [Related]
12. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
[TBL] [Abstract][Full Text] [Related]
13. Prognosis of patients with long COVID symptoms: a protocol for a longitudinal cohort study at a primary care referred outpatient clinic in Helsinki, Finland.
Virrantaus H; Liira H; Posharina T; Sulg A; Mäntylä T; Kanerva M; Laakso S; Sainio M; Malmivaara A; Vuokko A; Varonen M; Venäläinen M; Arokoski J
BMJ Open; 2023 Oct; 13(10):e072935. PubMed ID: 37848295
[TBL] [Abstract][Full Text] [Related]
14. Coinfection With SARS-CoV-2 and Influenza A(H1N1) in a Patient Seen at an Influenza-like Illness Surveillance Site in Egypt: Case Report.
Fahim M; Ghonim HAES; Roshdy WH; Naguib A; Elguindy N; AbdelFatah M; Hassany M; Mohsen A; Afifi S; Eid A
JMIR Public Health Surveill; 2021 Apr; 7(4):e27433. PubMed ID: 33784634
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
16. A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial.
García IG; Rodriguez-Rubio M; Mariblanca AR; de Soto LM; García LD; Villatoro JM; Parada JQ; Meseguer ES; Rosales MJ; González J; Arribas JR; Carcas AJ; de la Oliva P; Borobia AM
Trials; 2020 Jun; 21(1):466. PubMed ID: 32493475
[TBL] [Abstract][Full Text] [Related]
17. PEP-CoV protocol: a PEP flute-self-care randomised controlled trial to prevent respiratory deterioration and hospitalisation in early COVID-19.
Mollerup A; Larsen SC; Bennetzen AS; Henriksen M; Simonsen MK; Weis N; Kofod LM; Heitmann BL
BMJ Open; 2021 Jun; 11(6):e050582. PubMed ID: 34193503
[TBL] [Abstract][Full Text] [Related]
18. Prospective cohort study of children with suspected SARS-CoV-2 infection presenting to paediatric emergency departments: a Paediatric Emergency Research Networks (PERN) Study Protocol.
Funk AL; Florin TA; Dalziel SR; Mintegi S; Salvadori MI; Tancredi DJ; Neuman MI; Payne DC; Plint AC; Klassen TP; Malley R; Ambroggio L; Kim K; Kuppermann N; Freedman SB
BMJ Open; 2021 Jan; 11(1):e042121. PubMed ID: 33452195
[TBL] [Abstract][Full Text] [Related]
19. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
[TBL] [Abstract][Full Text] [Related]
20. Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial.
Aricò E; Castiello L; Bracci L; Urbani F; Lombardo F; Bacigalupo I; Ancidoni A; Vanacore N; Falcione A; Reggiani C; Dutti GM; Maglie MG; Papa O; Bartoletti PL; Ozzella G; Bevilacqua N; Nicastri E; Belardelli F; Sconocchia G
Trials; 2021 Sep; 22(1):584. PubMed ID: 34479601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
